Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
BCR-ABL TKI
Ponatinib
Iclusig · PONA
A third-generation BCR-ABL TKI potent against T315I, but carrying the highest vascular and hypertensive risk of the class.
ModerateBCR-ABL tyrosine kinase inhibitor · approved 2012
Chronic myeloid leukemia (T315I or resistant/intolerant)Philadelphia-positive acute lymphoblastic leukemia
Signature kidney injury
Hypertension
Ponatinib carries a black-box warning for arterial occlusive and thrombotic events and has the highest cardiovascular event rate among CML TKIs (about 41% in one comparative cohort; cumulative arterial occlusive events ~31% over 5 years in the PACE trial). Treatment-emergent hypertension is common; renal injury is largely a downstream consequence of hypertension and vascular disease.
Source: Cortes et al., Blood 2018 (PACE 5-year); Madaudo et al., ESC Heart Fail 2025
Mechanism of kidney injury
Potent VEGFR and off-target kinase inhibition drives endothelial dysfunction, reduced nitric-oxide bioavailability, hypertension, and accelerated arterial occlusive disease. The kidney is affected mainly through systemic and renovascular hypertension and reduced renal perfusion rather than direct tubular toxicity; severe or accelerated hypertension can cause hypertension-mediated (and rarely thrombotic-microangiopathic) kidney injury.
Clinical presentation
New or worsening hypertension, arterial occlusive/ischemic events, and peripheral arterial disease; creatinine may rise with poorly controlled hypertension or vascular compromise. Severe hypertensive surges can produce a TMA-like picture.
Onset
Hypertension can emerge early; arterial occlusive events accrue over months, with dose reduction mitigating risk.
Reversibility
Variable
Anticancer mechanism
Third-generation pan-BCR-ABL1 inhibitor active against the T315I gatekeeper mutation, with broad multikinase activity including VEGFR, FGFR, and PDGFR. Used in resistant/intolerant CML and Ph+ ALL.
Management
Treat hypertension promptly and to target; manage arterial events with cardiology/vascular input and consider dose reduction or interruption. Protecting the kidney centers on blood-pressure control and preserving renal perfusion; evaluate for TMA if MAHA accompanies a hypertensive crisis.
Risk factors
- Pre-existing hypertension and cardiovascular disease
- Higher ponatinib dose (45 mg vs reduced dosing)
- Older age and prior vascular events
- Diabetes and other cardiometabolic risk factors
Prevention
- Cardiovascular risk assessment and aggressive blood-pressure control
- Use the lowest effective dose; response-based dose reduction (PACE showed responses maintained after reduction)
- Monitor blood pressure, vascular status, and renal function
Note · Vascular toxicity and hypertension dominate; renal injury is a secondary, hypertension/perfusion-mediated effect rather than direct nephrotoxicity.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment is established (minimal renal excretion); dosing is driven instead by response and by mitigation of vascular toxicity (e.g., reduce to 15 mg on achieving response). Use caution in renal impairment given the vascular risk profile.
Dialyzability & ESKD dosing
Highly protein-bound and hepatically metabolized; not appreciably dialyzed and no supplemental dosing required in ESKD.
Differential diagnosis
Distinguish hypertension-mediated AKI and ischemic/atheroembolic injury from intrinsic nephrotoxicity (absent here) and from ponatinib-associated TMA; the dominant driver is the vascular phenotype.
Monitoring
- Blood pressure at every visit and home monitoring
- Serum creatinine periodically
- Vascular/cardiac symptom surveillance and ankle-brachial assessment when indicated
- Lipids and glucose
Key trials & series
- PACE (phase 2; 5-year arterial occlusive event and dose-reduction data)
- Madaudo et al. comparative TKI cardiovascular cohort (highest CV event rate with ponatinib)
Clinical pearls
- Ponatinib is the most vasculotoxic CML TKI - blood pressure control and the lowest effective dose are the renal protection strategy.
- Response is often maintained after dose reduction, so de-escalation reduces arterial events without sacrificing efficacy.
- Consider TMA if a hypertensive crisis is accompanied by hemolysis and thrombocytopenia.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
HypertensionPrerenal / Hemodynamic AKI
Beyond the kidney
Class-level context for the major non-renal toxicities of bcr-abl tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Vascular occlusion (ponatinib), fluid retention
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pleural effusions (dasatinib), PAH
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- QT, heart failure
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Moslehi JJ et al. · J Clin Oncol 2015 · PMID 26371140Authoritative review of ponatinib vascular toxicity and hypertension in CML.PMIDPonatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Cortes JE et al. · Blood 2018 · PMID 29567798Registrational PACE trial quantifying arterial occlusive events (~31% at 5 years) and the impact of dose reduction.PMIDCardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?Madaudo C et al. · ESC Heart Fail 2025 · PMID 39780756Reports the highest cardiovascular event rate (41%) with ponatinib among CML TKIs.PMIDCardiovascular toxic effects of targeted cancer therapy.Tajiri K et al. · Jpn J Clin Oncol 2017 · PMID 28531278Describes vascular/ischemic events and hypertension with ponatinib and nilotinib.PMIDNew drug toxicities in the onco-nephrology world.Perazella MA et al. · Kidney Int 2015 · PMID 25671763Onco-nephrology class context for TKI hypertension and vascular-mediated renal effects.PMIDPharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality.Ferreira A et al. · Nefrologia (Engl Ed) 2025 · PMID 40783302Cancer-center AKI series documenting the growing role of TKIs in drug-induced AKI requiring dialysis.
Related agents
Other agents sharing the same signature kidney injury.